The overall objective of this PDF project is to propose an integrated dose adaptation strategy that can be used in anticancer drug treatment. Indeed, many chemo agents used to treat tumors often induce dangerous side effects or toxicity, such as neutropenia [Crawford et al.] and hand-foot syndrome [Janusch et al.]. Since some tumors can only be destroyed by sufficiently high doses of chemotherapeutic agents, these harmful and lethal toxicities have become a main obstacle that limit the full use of the dosage of anticancer drugs or even force the discontinuation of chemo treatment.
Recent research at the University of Calgary has focused on shear walls and on evaluating the influence of various parameters on in-plane shear capacity. The reason for this is that, for example, while it is recognized by most researchers that compression on walls increases the shear strength of masonry, the quantification of this effect has been reported to vary from 40 to 70% [1,8] and the factors adopted by various design standards range from 0.25 up to 0.4.
Our immune system Is designed to protect us from harmful agents. It must initiate a rapid potent inflammatory response to eliminate invading pathogens. Although similar to the eradication of pathogens, the inflammatory response can also occur following a sterile injury and is required for tissue repair and wound healing. This includes trauma, ischaemia-reperfusion injury, autoimmunity or burn induced injury that occurs in the absence of any microorganisms.
Prolonged morphine treatment is known to cause an up-regulation of ORL1 receptors in the spinal cord (12, 13), which in turn is believed to contribute to the development of morphine tolerance by altering ?-opioid receptor mediate modulation of N-type calcium channels. Indeed, ORL1 antagonists can reverse the development of tolerance, and ORL1 knockout can mediate resistance to tolerance with no changes on the acute analgesic effects of morphine (14, 15). Our lab has shown that ORL1 receptors and Cav2.2 channels form a physical signaling complex that results in tonic G??
Electrical activity in the heart is controlled by the concerted activity of many proteins called ion-channels that regulate the transfer of different ions across cell membranes. Recently, researchers in biomedical science have identified that a particular component of sodium carrying ion-channel activity (called the persistent or late sodium current also known as (INa(P)) played a major role in controlling the electrical activity of the heart. More recent research suggests that this late sodium current may be involved in various cardiac diseases.
The principal objective of this proposal is to discover novel drugs to treat colon cancers. Currently colon cancer is a huge medical problem and there are many disadvantages to current drug therapies. These disadvantages include their ineffectiveness to completely eradicate cancers, causing toxic side effects and the development of multidrug resistance. A group of compounds discovered in the laboratory of the supervisor designated series 2 has significant potencies towards a number of human colon cancer cell lines.
Drug models describe the relationship between exposure (or pharmacokinetics), response (or pharmacodynamics) for both desired and undesired effects, and individual patient characteristics. In this project, drug models will be used to propose an integrated dose adaption strategy for cancer treatment. This strategy has a particular clinical value for our partner (InVentiv Health Clinical, a Contract Research Organization) because it would allow to better inform of the drug development process, thus reducing studies´ cost, drug development duration and risks in a long run.
L’amphotéricine B est la plus efficace et fréquemment l’unique traitement disponible pour diverses maladies à issue mortelle dont les infections fongiques systémiques et la leishmaniose viscérale. Les inconvénients du traitement contemporain à l’amphotéricine B sont sa toxicité et la nécessité d’administrer le médicament par voie intraveineuse en milieu hospitalier.
C’est en partenariat avec Labopharm, un chef de file de l’optimisation de la performance des médicaments à petites molécules que l’on effectuera l’étude pharmacocinétique complète de trois nouvelles formulations d’un médicament offert dans le commerce. Cette étude sera menée afin de choisir la formulation qui convient le mieux en termes de biodisponibilité et de taux d’absorption. Les paramètres pharmacocinétiques du médicament seront estimés à l’aide de différentes méthodes. On dégagera également les mécanismes associés à l’absorption, la distribution et l’élimination du médicament.
Les produits pharmaceutiques font partie des traitements de santé les plus importants et les plus utilisés au Canada. Les tiers payeurs du secteur des soins de santé comme les ministères provinciaux de la santé et les assureurs privés tels que la Croix Bleue et Green Shield, utilisent divers outils et techniques pour établir un juste équilibre entre l'accès, le coût et la qualité des médicaments.